PMM - Dosing underway in Reneo Pharma's mid-stage STRIDE study

Reneo Pharmaceuticals (RPHM) announces that the first patient has been dosed in Phase 2b STRIDE study.The trial is designed to evaluate the efficacy and safety of REN001 for the treatment of patients with primary mitochondrial myopathies ((PMM)). REN001 100 mg will be administered orally, once-daily for 24 weeks. Approx. 200 adult patients with PMM caused by alterations in mitochondrial DNA will be enrolled.The primary efficacy endpoint is the change from baseline in the distance walked during a 12-minute walk test after 24 weeks of treatment.Secondary efficacy endpoints include changes from baseline in the Modified Fatigue Impact Scale, Patient Global Impression of Change scale, and other patient-reported outcomes.Patients with PMM have genetic alterations that hamper the ability of their mitochondria to generate energy from nutrient sources, affecting multiple organ systems.

For further details see:

Dosing underway in Reneo Pharma's mid-stage STRIDE study